Ocular metipranolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in glaucoma and ocular hypertension.

Abstract

Metipranolol is a non-selective beta-adrenoceptor blocking agent used for the topical treatment of elevated intraocular pressure in patients with chronic open angle glaucoma or ocular hypertension. In double-blind comparative studies of up to 4 months duration, metipranolol 0.1 to 0.6% produced comparable reductions in intraocular pressure to timolol 0.25 to 0.5% and levobunolol 0.5%, lowering pressure by about 20 to 29% from baseline. Metipranolol has been well tolerated by most patients, producing only minor changes in objective measurements of ophthalmic status and systemic parameters. Similarly, subjective ophthalmic complaints have been minimal although reports of initial stinging or burning upon instillation have occurred. Further published reports, in which larger numbers of patients are treated over extended periods, are needed to confirm the drug's apparent long term comparative efficacy. Studies of ocular metipranolol to date are encouraging, and the drug demonstrates a lasting intraocular pressure reducing effect with good tolerability. Thus, ocular metipranolol provides a viable alternative to ocular timolol and levobunolol in the topical treatment of chronic open angle glaucoma or ocular hypertension.

• Authors: P E Battershill, E M Sorkin
• Journal: Drugs (Drugs) Vol. 36 Issue 5 Pg. 601-15 (Nov 1988) ISSN: 0012-6667 [Print] New Zealand
• PMID: 2905641 (Publication Type: Comparative Study, Journal Article, Review)

Chemical References

• Ophthalmic Solutions
• Propanolamines
• Metipranolol

Topics

• Glaucoma (drug therapy)
• Humans
• Metipranolol (administration & dosage, adverse effects, pharmacokinetics, pharmacology)
• Ocular Hypertension (drug therapy)
• Ophthalmic Solutions
• Propanolamines (administration & dosage, adverse effects, pharmacokinetics, pharmacology)